Brought to you by 
Kaleido Biosciences closes $101mm Series C round
26 Jun 2018
Executive Summary
Kaleido Biosciences (optimizing the human microbiome to treat disease) raised $101mm through its Series C round. Founding investor Flagship Pioneering participated, along with a subsidiary of the Abu Dhabi Investment Authority, Fidelity Management & Research, Invus, and Rock Springs Capital.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Kaleido Biosciences closes $101mm Series C round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice